As Chief Development Operations Officer at Tango Therapeutics, Yen-Ching Chua is responsible for driving integrated, high-quality and compliant development execution aligned with the company’s strategic priorities. She brings extensive global experience leading clinical and development operations across complex, multi‑regional portfolios.

Prior to joining Tango, Yen-Ching served as Vice President, Global Clinical Operations at Novocure and Head of Clinical Operations at Debiopharm International. She previously held senior leadership roles at MorphoSys AG and Novartis, where she built and led multinational teams, supported global regulatory approvals, and enhanced quality and operational rigor to accelerate patient impact.